Michael Michael

7.0k total citations · 1 hit paper
194 papers, 4.6k citations indexed

About

Michael Michael is a scholar working on Oncology, Surgery and Epidemiology. According to data from OpenAlex, Michael Michael has authored 194 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Oncology, 65 papers in Surgery and 48 papers in Epidemiology. Recurrent topics in Michael Michael's work include Neuroendocrine Tumor Research Advances (44 papers), Lung Cancer Research Studies (44 papers) and Neuroblastoma Research and Treatments (34 papers). Michael Michael is often cited by papers focused on Neuroendocrine Tumor Research Advances (44 papers), Lung Cancer Research Studies (44 papers) and Neuroblastoma Research and Treatments (34 papers). Michael Michael collaborates with scholars based in Australia, United States and New Zealand. Michael Michael's co-authors include Trevor Leong, Rodney J. Hicks, Kathryn Field, Alexander G. Heriot, Andrew M. Scott, Frank Caruso, Kristofer J. Thurecht, Mattias Björnmalm, Grace Kong and John Zalcberg and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Michael Michael

182 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A gut microbial signature for combination immune checkpoint blockade across cancer types

2024 67 citations Ashray Gunjur, Yan Shao et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Michael Australia	36	2.2k	1.3k	1.2k	898	805	194	4.6k
Romain Coriat France	40	2.7k 1.3×	1.3k 1.0×	1.6k 1.3×	1.1k 1.2×	760 0.9×	287	5.2k
Omar Abdel‐Rahman Egypt	36	2.9k 1.3×	974 0.8×	1.7k 1.4×	874 1.0×	964 1.2×	331	5.1k
Diamantis I. Tsilimigras United States	36	2.2k 1.0×	2.2k 1.7×	1.3k 1.0×	891 1.0×	601 0.7×	305	5.4k
Thomas Aparicio France	40	3.6k 1.6×	1.8k 1.4×	2.1k 1.7×	1.5k 1.6×	716 0.9×	254	6.5k
Steven N. Hochwald United States	47	3.2k 1.5×	3.0k 2.4×	2.7k 2.2×	1.1k 1.2×	1.3k 1.7×	210	7.4k
Olivier Mir France	43	2.9k 1.3×	760 0.6×	2.8k 2.3×	655 0.7×	1.2k 1.5×	287	6.4k
Rossana Berardi Italy	45	4.2k 1.9×	1.1k 0.9×	2.8k 2.3×	569 0.6×	1.9k 2.3×	344	7.4k
Deepali Jain India	33	1.3k 0.6×	990 0.8×	1.8k 1.5×	788 0.9×	858 1.1×	282	4.6k
Syed A. Hussain United Kingdom	37	1.4k 0.7×	2.4k 1.9×	964 0.8×	502 0.6×	1.4k 1.7×	231	5.4k
Nipun B. Merchant United States	48	5.0k 2.3×	2.1k 1.6×	2.0k 1.6×	1.1k 1.3×	1.7k 2.1×	212	7.7k

Countries citing papers authored by Michael Michael

Since Specialization

Citations

This map shows the geographic impact of Michael Michael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Michael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Michael more than expected).

Fields of papers citing papers by Michael Michael

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Michael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Michael. The network helps show where Michael Michael may publish in the future.

Co-authorship network of co-authors of Michael Michael

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Michael. A scholar is included among the top collaborators of Michael Michael based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Michael. Michael Michael is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Neill, Niamh, David W. Johnson, Aisling Kelly, et al.. (2025). A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function. EClinicalMedicine. 82. 103101–103101.

Gunjur, Ashray, Yan Shao, Oliver Klein, et al.. (2024). A gut microbial signature for combination immune checkpoint blockade across cancer types. Nature Medicine. 30(3). 797–809. 67 indexed citations breakdown →

Ramsay, Robert G., Catherine Mitchell, Shienny Sampurno, et al.. (2024). A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer. Heliyon. 11(1). e41364–e41364. 2 indexed citations

Krishnasamy, Mei, Senthil Lingaratnam, Sam Harris, et al.. (2023). Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey. Clinical and Translational Science. 16(12). 2700–2708. 2 indexed citations

Clark, Molly S., Nicholas J. Clemons, Frédéric Hollande, et al.. (2023). Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review. Langenbeck s Archives of Surgery. 408(1). 392–392. 5 indexed citations

Gough, Karla, Allison Drosdowsky, Timothy Price, et al.. (2023). The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis. Supportive Care in Cancer. 31(10). 577–577. 1 indexed citations

Michael, Michael & Diana Elizabeth Waturangi. (2023). Antibiofilm activity from endophyte bacteria, Vibrio cholerae strains, and actinomycetes isolates in liquid and solid culture. BMC Microbiology. 23(1). 83–83. 3 indexed citations

Michael, Michael, et al.. (2023). The neuroprotective effect of statin in traumatic brain injury: A systematic review. World Neurosurgery X. 19. 100211–100211. 17 indexed citations

Gough, Karla, et al.. (2022). Prevalence of malnutrition and nutrition‐related complications in patients with gastroenteropancreatic neuroendocrine tumours. Journal of Neuroendocrinology. 34(6). e13116–e13116. 6 indexed citations

10.

Alexander, Marliese, Smaro Lazarakis, Jennifer Martin, et al.. (2022). A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. British Journal of Cancer. 127(1). 126–136. 14 indexed citations

11.

Tacey, Mark, Benjamin Thomson, Michael Michael, et al.. (2022). Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. European Journal of Cancer. 174. 102–112. 19 indexed citations

12.

Hicks, Rodney J., Nick Pavlakis, Emma Link, et al.. (2020). The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (¹⁸F) positron‐emission tomography positive intermediate grade pancreatic neuroendocrine tumors. Asia-Pacific Journal of Clinical Oncology. 16(3). 150–157. 2 indexed citations

13.

Ng, Sweet Ping, Julie Chu, Sarat Chander, et al.. (2020). Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial). Radiotherapy and Oncology. 155. 27–32. 6 indexed citations

14.

Klein, Oliver, Damien Kee, Ben Markman, et al.. (2020). Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clinical Cancer Research. 26(17). 4454–4459. 116 indexed citations

15.

Gough, Karla, Allison Drosdowsky, Timothy Price, et al.. (2019). Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR Research Protocols. 8(12). e14361–e14361. 3 indexed citations

16.

Behrenbruch, Corina, Sophie Paquet‐Fifield, Christina Mølck, et al.. (2018). Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process. Clinical & Experimental Metastasis. 35(4). 333–345. 51 indexed citations

17.

Björnmalm, Mattias, Kristofer J. Thurecht, Michael Michael, Andrew M. Scott, & Frank Caruso. (2017). Bridging Bio–Nano Science and Cancer Nanomedicine. ACS Nano. 11(10). 9594–9613. 313 indexed citations

18.

Lynch, A. Craig, Timothy Akhurst, Samuel Y. Ngan, et al.. (2014). Systematic Review of FDG-PET Prediction of Complete Pathological Response and Survival in Rectal Cancer. Annals of Surgical Oncology. 21(11). 3598–3607. 34 indexed citations

19.

Goel, Shom, Jacquie Chirgwin, Prudence A. Francis, et al.. (2010). Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. The Breast. 20(2). 101–110. 10 indexed citations

20.

Dooley, Michael, et al.. (2003). Implications of dose rounding of chemotherapy to the nearest vial size. Supportive Care in Cancer. -1(1). 1–1. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact